Literature DB >> 8892343

Inflammatory mechanisms in neurodegeneration and Alzheimer's disease: the role of the complement system.

G M Pasinetti1.   

Abstract

This review discusses key findings indicating potential roles of the complement (C)-system in chronic inflammation in Alzheimer's disease (AD) brain. Although there is no means to cure or prevent the disease, recent studies suggest that antiinflammatory drugs may delay the onset of AD dementia. One target of these drugs may be the (C)-system, which is best known for its roles in inflammatory processes in peripheral tissues. However, recent data show C-system expression and regulation in brain cells, and C-system protein deposition in AD plaques. It is still nuclear whether C-system activation contributes to neuropathology in the AD brain, as shown in multiple sclerosis (MS). New clinical studies with antiinflammatory agents are now under general consideration by the Alzheimer's Disease Cooperative Study program. In this review I outline research directions which address possible C-system contributions to neurodegeneration. Finally, I discuss potential pharmacological interventions designed to control segments of classical inflammatory cascades in which the C-system is highly implicated. These aspects are critical to the understanding of C-mediated responses in normal and pathologic brain.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8892343     DOI: 10.1016/0197-4580(96)00113-3

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  23 in total

1.  Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner.

Authors:  L Bergamaschini; S Canziani; B Bottasso; M Cugno; P Braidotti; A Agostoni
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

Review 2.  Complement in central nervous system inflammation.

Authors:  Scott R Barnum
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 3.  Single cell gene expression profiling in Alzheimer's disease.

Authors:  Stephen D Ginsberg; Shaoli Che; Scott E Counts; Elliott J Mufson
Journal:  NeuroRx       Date:  2006-07

Review 4.  Is there a future for cyclo-oxygenase inhibitors in Alzheimer's disease?

Authors:  Lap Ho; Weiping Qin; Breton S Stetka; Giulio M Pasinetti
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 5.  Glucocorticoids in Alzheimer's disease. The story so far.

Authors:  P S Aisen; G M Pasinetti
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

Review 6.  Neuroimmune nexus of depression and dementia: Shared mechanisms and therapeutic targets.

Authors:  Francis J Herman; Sherry Simkovic; Giulio M Pasinetti
Journal:  Br J Pharmacol       Date:  2019-03-21       Impact factor: 8.739

Review 7.  The role of the amyloid protein precursor (APP) in Alzheimer's disease: does the normal function of APP explain the topography of neurodegeneration?

Authors:  D H Small
Journal:  Neurochem Res       Date:  1998-05       Impact factor: 3.996

8.  Increased intrathecal inflammatory activity in frontotemporal dementia: pathophysiological implications.

Authors:  M Sjögren; S Folkesson; K Blennow; E Tarkowski
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

9.  Complement C5 in experimental autoimmune encephalomyelitis (EAE) facilitates remyelination and prevents gliosis.

Authors:  Susanna H Weerth; Horea Rus; Moon L Shin; Cedric S Raine
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

10.  Implication of complement system and its regulators in Alzheimer's disease.

Authors:  Martin V Kolev; Marieta M Ruseva; Claire L Harris; B Paul Morgan; Rossen M Donev
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.